Autumn Clark, DO
Psychiatry · Springfield, MONPI 1912911090
Payments from drug & device makers
Across 277 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$1K
- AbbVie$939
- Teva Pharmaceuticals USA, Inc.$255
- E.r. Squibb & Sons, L.L.C.$211
- Otsuka America Pharmaceutical, Inc.$195
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$183
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,95695%
- Education$2185%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 98 | $1,298 |
| AbbVie(2 entities) | 62 | $939 |
| Teva Pharmaceuticals USA, Inc. | 10 | $255 |
| E.r. Squibb & Sons, L.L.C. | 16 | $211 |
| Otsuka America Pharmaceutical, Inc. | 12 | $195 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $183 |
| Neurocrine Biosciences, Inc. | 7 | $172 |
| Sunovion Pharmaceuticals Inc. | 12 | $161 |
| Johnson & Johnson | 9 | $137 |
| Indivior Inc. | 5 | $112 |
| Alkermes, Inc. | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $89 |
| Corium, LLC | 3 | $73 |
| Merck | 4 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $48 |
| Lundbeck LLC | 2 | $34 |
| Hikma Pharmaceuticals USA | 1 | $28 |
| Collegium Pharmaceutical, Inc. | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$4,174 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 74 | $614,641 |
| Invega SustennaPaliperidone Palmitate | 73 | $265,352 |
| AustedoDeutetrabenazine | 21 | $184,936 |
| VraylarCariprazine Hcl | 94 | $132,390 |
| LybalviOlanzapine/Samidorphan Malate | 55 | $88,589 |
| NuedextaDextromethorphan Hbr/Quinidine | 66 | $72,944 |
| TrintellixVortioxetine Hydrobromide | 127 | $72,797 |
| CaplytaLumateperone Tosylate | 40 | $66,496 |
| RexultiBrexpiprazole | 42 | $65,172 |
| Abilify MaintenaAripiprazole | 19 | $55,153 |
| BelsomraSuvorexant | 81 | $35,680 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $26,537 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 163 | $20,719 |
| Lurasidone Hcl | 128 | $19,374 |
| VyvanseLisdexamfetamine Dimesylate | 49 | $18,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $172 | $614,64174 claims |
| Johnson & JohnsonInvega Sustenna | $137 | $265,35273 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $255 | $184,93621 claims |
| AbbVieVraylar, Savella | $939 | $138,390106 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $195 | $120,32561 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $89 | $90,964176 claims |
| Alkermes, Inc.Lybalvi | $111 | $88,58955 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $48 | $72,94466 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $183 | $66,49640 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $28 | $36,303264 claims |
| MerckBelsomra | $58 | $35,68081 claims |
| Indivior Inc.Suboxone | $112 | $26,53739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Springfield
- Alok JainSpringfield$64K
- Lorri DarrowSpringfield$47K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.